Studying memory and thinking decline in older adults with late life depression
Studies brain changes and thinking decline in people aged 65 and older with depression.
Plain-language title generated from the registry record
Registry title: Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project
Key facts
- Where
- Pittsburgh and San Francisco, United StatesSee the 2 sites
Where in United States
- University of PittsburghPittsburgh, United StatesNo longer taking part
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Southern California
- Trial code
- NCT02434393
- Record updated
- 25 November 2025
- Original description
The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD).Read full original descriptionShow less
Characterizing Cognitive Decline in Late Life Depression: The Alzheimer's Disease Neuroimaging Initiative - Depression Project
The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD).
This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison.
Depression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.
Inclusion: Individual participated in original Characterizing Cognitive Decline in Late Life Depression study or Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression Study; Exclusion Exceptions:; Antidepressant medication treatment is allowed only if the medication dose is stable for 4 weeks prior to the MRI scan; Psychotherapy interventions is allowed only if they have completed at least 4 weeks of individual or group psychotherapy intervention prior to the MRI scan; Participants taking cognitive enhancing medications will be able to enter the study.